Intranasal Dexmedetomidine Combined With Esketamine for Emergence Quality After Suspension Laryngoscopy
Key facts
- Who runs it
- The First Hospital of Jilin University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 134 people, planned
- Started
- Sept 2026
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dexmedetomidin
- Esketamine
- Record updated
- 19 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- 1. Aged 18-65 years, male or female. 2. ASA physical status Ⅰ or Ⅱ. 3. Scheduled for elective surgery under general anesthesia with tracheal intubation; Expected operation duration 30-180 minutes. 5. Able to understand the study content and sign written informed consent voluntarily
Who cannot take part
- 1. Preoperative cognitive dysfunction or psychiatric disorders. 2. Known allergy to dexmedetomidine or esketamine. 3. Severe cardiac, respiratory, hepatic or renal insufficiency. 4. Predicted difficult airway. 5. Drug abuse or long-term use of sedatives. 6. Pregnant or breastfeeding women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a single-center, prospective, single-blinded, randomized controlled trial conducted at The First Hospital of Jilin University. A total of 134 adult patients aged 18-65 years with ASA Ⅰ-Ⅲ undergoing elective laryngoscopic surgery for vocal cord polyps will be enrolled. Subjects will be randomly assigned into two groups. The control group receives intranasal dexmedetomidine plus intravenous normal saline before anesthesia induction. The combination group receives the same dose of intranasal dexmedetomidine plus intravenous esketamine before induction. The primary objective is to compare the incidence of emergence agitation within 60 minutes after extubation. Secondary outcomes include hemodynamic changes, adverse events, recovery time, PACU stay, postoperative sore throat pain and quality of recovery at 24 hours. Standardized anesthesia induction and maintenance will be applied for all patients. The study aims to explore whether the combination of intranasal dexmedetomidine and esketamine improves recovery quality in patients undergoing suspension laryngoscopy.
The 2 groups in the trial
- Control GroupExisting treatment, for comparison
Patients receive dexmedetomidine before anesthesia induction.
Treatment: Dexmedetomidin
- Intervention GropTreatment being tested
Patients receive dexmedetomidine combined with esketamine before anesthesia induction.
Treatment: Dexmedetomidin and Esketamine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Dexmedetomidine Nasal Spray Combined With Esketamine on the Quality of Recovery in Patients Undergoing Suspension Laryngoscopy Surgery
- Criteria questions
- Built from NCT07880938, who can take part
- Record updated
- 19 October 2026